Literature DB >> 3937265

Assay of human tissue-type plasminogen activator (t-PA) with an enzyme-linked immunosorbent assay (ELISA) based on three murine monoclonal antibodies to t-PA.

P Holvoet, H Cleemput, D Collen.   

Abstract

An enzyme-linked immunosorbent assay (ELISA) for the measurement of human tissue-type plasminogen activator (t-PA) was developed. Microtiter plates were coated with a mixture of two monoclonal antibodies and bound t-PA was quantitated with a third monoclonal antibody linked to peroxidase. The lower limit of sensitivity of the assay was 0.2 ng of t-PA per ml. The concentration of antigen in citrated plasma of human subjects was found to be 3.4 +/- 0.8 ng/ml. The assay had a good reproducibility with values of 3.8, 6.5 and 4.9 percent respectively for the intra-, inter-assay and inter-dilution variation coefficients. The results of the ELISA assay on plasma samples from patients during thrombolytic therapy with t-PA correlated very well, over a wide concentration range, with those obtained with a previously described two-site immuno-radiometric assay (r = 0.96). This ELISA with monoclonal antibodies constitutes a stable and reproducible set of reagents for the measurement of t-PA antigen in biological fluids, avoiding the disadvantages of the use of radioisotopes and of polyclonal antibodies.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3937265

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  14 in total

1.  Hyperfibrinolysis in hepatosplenic schistosomiasis.

Authors:  N E el-Bassiouni; A E el Bassiouny; H R el-Khayat; M M Akl; S A Omran
Journal:  J Clin Pathol       Date:  1996-12       Impact factor: 3.411

2.  Imbalance of tissue-type plasminogen activator (t-PA) and its specific inhibitor (PAI-1) in patients with rheumatoid arthritis associated with disease activity.

Authors:  L T Kopeikina; E F Kamper; V Koutsoukos; Y Bassiakos; I Stavridis
Journal:  Clin Rheumatol       Date:  1997-05       Impact factor: 2.980

3.  Recombinant plasminogen activator inhibitor-1 reverses the bleeding tendency associated with the combined administration of tissue-type plasminogen activator and aspirin in rabbits.

Authors:  D E Vaughan; P J Declerck; M De Mol; D Collen
Journal:  J Clin Invest       Date:  1989-08       Impact factor: 14.808

4.  A Common Calibrator Does Not Secure Harmonisation of Commercial t-PA and PAI-1 Antigen Measurements.

Authors:  Moniek P M de Maat; Jorgen Gram; Jorgen Jespersen; Cornelis Kluft
Journal:  EJIFCC       Date:  2001-07-22

Review 5.  Tissue-type plasminogen activator. A review of its pharmacology and therapeutic use as a thrombolytic agent.

Authors:  D Collen; H R Lijnen; P A Todd; K L Goa
Journal:  Drugs       Date:  1989-09       Impact factor: 9.546

6.  The Association of Anticoagulant Protein Concentrations with Acute Myocardial Infarction in the Thromholysis in Myocardial Infarction Phase II (TIMI II) Trial.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1998       Impact factor: 2.300

7.  Interleukin-6 and coagulation-fibrinolysis fluctuations after laparoscopic and conventional cholecystectomy.

Authors:  G Vander Velpen; F Penninckx; R Kerremans; J Van Damme; J Arnout
Journal:  Surg Endosc       Date:  1994-10       Impact factor: 4.584

8.  Establishment of permanent human endothelial cells achieved by transfection with SV40 large T antigen that retain typical phenotypical and functional characteristics.

Authors:  F Moldovan; H Benanni; J Fiet; O Cussenot; J Dumas; C Darbord; H R Soliman
Journal:  In Vitro Cell Dev Biol Anim       Date:  1996-01       Impact factor: 2.416

Review 9.  Clinical disorders of fibrinolysis: a critical review.

Authors:  R B Francis
Journal:  Blut       Date:  1989-07

10.  Reduction of contact activation related fibrinolytic activity in factor XII deficient patients. Further evidence for the role of the contact system in fibrinolysis in vivo.

Authors:  M Levi; C E Hack; J P de Boer; D P Brandjes; H R Büller; J W ten Cate
Journal:  J Clin Invest       Date:  1991-10       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.